Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
HER2-expressing Cancers
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and eliminates ZW25 (pharmacokinetics or PK).

Provided treatments

  • Drug: ZW25 (Zanidatamab)
  • Drug: Paclitaxel
  • Drug: Capecitabine
  • Drug: Vinorelbine
  • Drug: Tucatinib
  • Drug: Tucatinib
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02892123. The sponsor of the trial is Zymeworks Inc. and it is looking for 418 volunteers for the current phase.
Official trial title:
Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers